CLAUDIN18 antibodies and methods of treating cancer

US12345709B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventors

• Dylan Conklin · Los Angeles, US
• Martina S. McDermott · Los Angeles, US
• Neil A. O'Brien · Los Angeles, US
• Michael J. Palazzolo · Los Angeles, US
• Dennis Slamon · Los Angeles, US

Key dates

• Filing date: Jul 17, 2020
• Grant date: Jul 1, 2025
• Expiry date: Jul 26, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides antigen-binding proteins which bind to Claudin-18.2 (CLDN18.2); bispecific antigen-binding proteins which bind to CLDN18.2 and a second antigen; and conjugates thereof. In various aspects, the antigen-binding proteins bind to Extracellular Loop 1 (EL1) of the extracellular domain of CLDN18.2. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.